NCT00882310View on ClinicalTrials.gov

A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV

DRUG

Docetaxel

Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV

DRUG

Capecitabine

Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing

All Listed Sponsors
lead

Columbia University

OTHER

NCT00882310 - A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer | Biotech Hunter | Biotech Hunter